Latest news

• Lilly expands dermatology portfolio with $1.1bn Dermira deal

  The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a

• MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

  Atopic dermatitis was poorly-served with therapies for years, but latterly has seen new treatment options come to market including Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent ... There are a number of drugs coming through the collective

• FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

  Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic

• GSK’s Nucala gets boost with self-administration approval

  The drug earned £152m ($193m) in Q1 this year (up 41% on the same period a year earlier) but is also facing competition from other IL-5 inhibitors including AstraZeneca’s  ... Another significant challenger in the market is Sanofi's Dupixent, a dual

• Sanofi's Dupixent gains asthma approval in Europe

  The dual IL-4 and IL-13 inhibitor has just gained approval for the new use in the European Union, and the partners are amassing data which shows it can alleviate